Joel Greenblatt's HALO Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 252,934 shares of Halozyme Therapeutics, Inc. (HALO) worth $18.55 M, representing 0.08% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 184,882 shares. Largest reduction occurred in Q1 2024, reducing 55,975 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2015 | +36,701 | New Buy | 36,701 | $22.59 |
| Q3 2015 | -7,746 | Reduce 21.11% | 28,955 | $13.43 |
| Q4 2015 | -28,955 | Sold Out | 28,955 | $0.00 |
| Q2 2016 | +34,313 | New Buy | 34,313 | $8.63 |
| Q3 2016 | -34,313 | Sold Out | 34,313 | $0.00 |
| Q1 2018 | +115,942 | New Buy | 115,942 | $19.59 |
| Q2 2018 | -53,741 | Reduce 46.35% | 62,201 | $16.86 |
| Q3 2018 | -62,201 | Sold Out | 62,201 | $0.00 |
| Q2 2019 | +12,970 | New Buy | 12,970 | $17.19 |
| Q3 2019 | +364 | Add 2.81% | 13,334 | $15.52 |
| Q4 2019 | -13,334 | Sold Out | 13,334 | $0.00 |
| Q1 2020 | +17,729 | New Buy | 17,729 | $17.99 |
| Q2 2020 | +3,153 | Add 17.78% | 20,882 | $26.82 |
| Q3 2020 | +8 | Add 0.04% | 20,890 | $26.28 |
| Q4 2020 | +349 | Add 1.67% | 21,239 | $42.70 |
| Q1 2021 | +25,085 | Add 118.11% | 46,324 | $41.68 |
| Q2 2021 | -11,946 | Reduce 25.79% | 34,378 | $45.41 |
| Q3 2021 | -10,943 | Reduce 31.83% | 23,435 | $40.67 |
| Q4 2021 | +21,698 | Add 92.59% | 45,133 | $40.21 |
| Q1 2022 | -6,231 | Reduce 13.81% | 38,902 | $39.87 |
| Q2 2022 | -8,407 | Reduce 21.61% | 30,495 | $44.01 |
| Q3 2022 | -905 | Reduce 2.97% | 29,590 | $39.54 |
| Q4 2022 | -2,143 | Reduce 7.24% | 27,447 | $56.90 |
| Q1 2023 | +16,424 | Add 59.84% | 43,871 | $38.19 |
| Q2 2023 | -7,918 | Reduce 18.05% | 35,953 | $36.07 |
| Q3 2023 | +6,153 | Add 17.11% | 42,106 | $38.20 |
| Q4 2023 | +55,782 | Add 132.48% | 97,888 | $36.96 |
| Q1 2024 | -55,975 | Reduce 57.18% | 41,913 | $40.68 |
| Q2 2024 | -13,537 | Reduce 32.30% | 28,376 | $52.36 |
| Q3 2024 | +14,886 | Add 52.46% | 43,262 | $57.24 |
| Q4 2024 | +4,178 | Add 9.66% | 47,440 | $47.81 |
| Q1 2025 | -14,909 | Reduce 31.43% | 32,531 | $63.81 |
| Q2 2025 | +35,521 | Add 109.19% | 68,052 | $52.02 |
| Q3 2025 | +184,882 | Add 271.68% | 252,934 | $73.34 |
Joel Greenblatt's Halozyme Therapeutics Investment FAQs
Joel Greenblatt first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2015, acquiring 36,701 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Halozyme Therapeutics, Inc. (HALO) for 42 quarters since Q2 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q3 2025, adding 252,934 shares worth $18.55 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 252,934 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $18.55 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.08% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Halozyme Therapeutics, Inc. (HALO) was 252,934 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.